Robert M. Rifkin
About
Robert M. Rifkin is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Robert M. Rifkin has authored 143 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 72 papers in Oncology and 67 papers in Molecular Biology. Recurrent topics in Robert M. Rifkin's work include Multiple Myeloma Research and Treatments (102 papers), Protein Degradation and Inhibitors (54 papers) and Cancer Treatment and Pharmacology (29 papers). Robert M. Rifkin is often cited by papers focused on Multiple Myeloma Research and Treatments (102 papers), Protein Degradation and Inhibitors (54 papers) and Cancer Treatment and Pharmacology (29 papers). Robert M. Rifkin collaborates with scholars based in United States, United Kingdom and Canada. Robert M. Rifkin's co-authors include Ian W. Flinn, Mohamad A. Hussein, Stephen J. Noga, Parameswaran Hari, Paul G. Richardson, Iain J. Webb, Shaji Kumar, Natalie S. Callander, S. Vincent Rajkumar and Hongliang Shi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.
In The Last Decade
Robert M. Rifkin
139 papers receiving 2.4k citations
Peers
Robert M. Rifkin
Hareth Nahi Sweden
Edward N. Libby United States
Peter Gimsing Denmark
Ivan Špıčka Czechia
William Deraedt United States
Lionel Karlin France
Amir T. Fathi United States
Martin Kropff Germany
Ellen K. Ritchie United States
Bruno Nervi Chile
Citations per year, relative to Robert M. Rifkin Robert M. Rifkin (= 1×)
peers
Hareth Nahi
Countries citing papers authored by Robert M. Rifkin
Since
Specialization
Citations
This map shows the geographic impact of Robert M. Rifkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Rifkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Rifkin more than expected).
Fields of papers citing papers by Robert M. Rifkin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert M. Rifkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Rifkin. The network helps show where Robert M. Rifkin may publish in the future.
Co-authorship network of co-authors of Robert M. Rifkin
This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Rifkin. A scholar is included among the top collaborators of Robert M. Rifkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Rifkin. Robert M. Rifkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ailawadhi, Sikander, Hans C. Lee, James Omel, et al.. (2024). Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry. Blood Cancer Journal. 14(1). 198–198.
2.
Rifkin, Robert M., Gary A. Simmons, Christopher A. Yasenchak, et al.. (2024). OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(16_suppl). 7528–7528.
3.
Lee, Hans C., Karthik Ramasamy, Katja Weisel, et al.. (2022). Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clinical Lymphoma Myeloma & Leukemia. 23(2). 112–122.
4.
Gasparetto, Cristina, Sundar Jagannath, Robert M. Rifkin, et al.. (2021). Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clinical Lymphoma Myeloma & Leukemia. 22(3). 149–157.
5.
Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925.
6.
Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2018). Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Advances. 2(13). 1608–1615.
7.
Rifkin, Robert M., Sundar Jagannath, Brian G.M. Durie, et al.. (2018). Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clinical Therapeutics. 40(7). 1193–1202.e1.
8.
Abonour, Rafat, Lynne I. Wagner, Brian G.M. Durie, et al.. (2018). Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. Annals of Hematology. 97(12). 2425–2436.
9.
Rifkin, Robert M., Ralph V. Boccia, Suman Kambhampati, et al.. (2017). Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen. Blood. 130. 5407–5407.
10.
Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2017). Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 130. 1839–1839.
11.
Ailawadhi, Sikander, Maral DerSarkissian, Mei Sheng Duh, et al.. (2017). Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 130. 5599–5599.
12.
Rifkin, Robert M., E. Susan Amirian, Thomas W. Wilson, et al.. (2017). Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting. Blood. 130. 3433–3433.
13.
Shah, Jatin J., Rafat Abonour, Christina Gasparetto, et al.. (2017). Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clinical Lymphoma Myeloma & Leukemia. 17(9). 575–583.e2.
14.
Balch, Alan, Charles M. Balch, Al B. Benson, et al.. (2016). Recommendations for the Role of Clinical Pathways in an Era of Personalized Medicine. The American Journal of Managed Care. 22.
15.
Lonial, Sagar, Habte Yimer, María‐Victoria Mateos, et al.. (2016). KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). Annals of Oncology. 27. viii16–viii16.
16.
Assouline, Sarit, Elizabeth Chang, Bruce D. Cheson, et al.. (2014). Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer Journal. 4(10). e251–e251.
17.
Rifkin, Robert M., et al.. (2007). Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. Clinical Lymphoma & Myeloma. 7. S150–S155.
18.
Wilkins, Ross M., et al.. (2003). Percutaneous Treatment of Long Bone Nonunions: The Use of Autologous Bone Marrow and Allograft Bone Matrix. Orthopedics. 26(5). s549–54.
19.
Gale, Robert Peter, Rolla Edward Park, Robert W. Dubois, et al.. (1999). Delphi-Panel Analysis of Appropriateness of High-Dose Therapy and Bone Marrow Autotransplants in Newly Diagnosed Multiple Myeloma. Leukemia & lymphoma. 33(5-6). 511–519.
20.
Rifkin, Robert M., Barbara R. Reed, Fred W. Hetzel, & Kun Chen. (1997). Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report. Clinical Therapeutics. 19(4). 639–641.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hareth Nahi Breakdown of academic impact, for papers by Edward N. Libby Breakdown of academic impact, for papers by Peter Gimsing Breakdown of academic impact, for papers by Ivan Špıčka Breakdown of academic impact, for papers by William Deraedt Breakdown of academic impact, for papers by Lionel Karlin Breakdown of academic impact, for papers by Amir T. Fathi Breakdown of academic impact, for papers by Martin Kropff Breakdown of academic impact, for papers by Ellen K. Ritchie Breakdown of academic impact, for papers by Bruno Nervi